Advertisement
ACHV vs OGEN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACHV is a StrongBuy and OGEN is a Hold.
ACHV in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 16, 2026
ACHV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 43 cases where ACHV's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACHV's RSI Indicator exited the oversold zone, 23 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for ACHV just turned positive on October 28, 2026. Looking at past instances where ACHV's MACD turned positive, the stock continued to rise in 34 of 43 cases over the following month. The odds of a continued upward trend are 79%.
Following a +6.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACHV advanced for three days, in 212 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 54 cases where ACHV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACHV as a result. In 65 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The 10-day moving average for ACHV crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACHV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for ACHV entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-47.118) is normal, around the industry mean (3.498). P/E Ratio (-4.048) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. ACHV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACHV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
OGEN in upward trend: price may jump up because it broke its lower Bollinger Band on October 27, 2026
OGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 40 cases where OGEN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where OGEN advanced for three days, in 154 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OGEN as a result. In 87 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for OGEN turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 39 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for OGEN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.429) is normal, around the industry mean (3.498). P/E Ratio (0.356) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. OGEN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ACHV | OGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 19 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 61 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 48 | 85 | |
P/E GROWTH RATING 1..100 | 56 | 1 | |
SEASONALITY SCORE 1..100 | 50 | 28 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACHV's Valuation (3) in the Biotechnology industry is somewhat better than the same rating for OGEN (61). This means that ACHV’s stock grew somewhat faster than OGEN’s over the last 12 months.
ACHV's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as OGEN (100). This means that ACHV’s stock grew similarly to OGEN’s over the last 12 months.
ACHV's SMR Rating (100) in the Biotechnology industry is in the same range as OGEN (100). This means that ACHV’s stock grew similarly to OGEN’s over the last 12 months.
ACHV's Price Growth Rating (48) in the Biotechnology industry is somewhat better than the same rating for OGEN (85). This means that ACHV’s stock grew somewhat faster than OGEN’s over the last 12 months.
OGEN's P/E Growth Rating (1) in the Biotechnology industry is somewhat better than the same rating for ACHV (56). This means that OGEN’s stock grew somewhat faster than ACHV’s over the last 12 months.
| ACHV | OGEN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 72% | 2 days ago 81% |
| Stochastic ODDS (%) | 2 days ago 76% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 81% | 3 days ago 90% |
| MACD ODDS (%) | 2 days ago 79% | 3 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 90% |
| Advances ODDS (%) | 3 days ago 80% | 3 days ago 76% |
| Declines ODDS (%) | 10 days ago 82% | 9 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACHV’s FA Score shows that 1 FA rating(s) are green while OGEN’s FA Score has 1 green FA rating(s).
- ACHV’s FA Score: 1 green, 4 red.
- OGEN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACHV’s TA Score shows that 4 TA indicator(s) are bullish while OGEN’s TA Score has 4 bullish TA indicator(s).
- ACHV’s TA Score: 4 bullish, 5 bearish.
- OGEN’s TA Score: 4 bullish, 4 bearish.
Price Growth
ACHV (@Biotechnology) experienced а +0.74% price change this week, while OGEN (@Biotechnology) price change was -7.30% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ACHV is expected to report earnings on Mar 11, 2027.
OGEN is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ACHV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACHV has been loosely correlated with BEAM. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ACHV jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To ACHV | 1D Price Change % | ||
|---|---|---|---|---|
| ACHV | 100% | N/A | ||
| BEAM - ACHV | 38% Loosely correlated | -6.92% | ||
| ABCL - ACHV | 36% Loosely correlated | -0.32% | ||
| OGEN - ACHV | 35% Loosely correlated | -3.30% | ||
| CRSP - ACHV | 34% Loosely correlated | -9.77% | ||
| ALLO - ACHV | 34% Loosely correlated | -12.08% | ||
More | ||||